Latest Breaking News On - Todd zavodnick - Page 1 : comparemela.com

Tapinarof Cream Under Review for Atopic Dermatitis

Dermatology Month in Review: April 2024

In this review of dermatology news in April, we highlighted several major stories on such topics as cutaneous reactions to COVID-19, topical versus oral minoxidil, and FDA news.

Tapinarof Cream Under Review for Atopic Dermatitis

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for tapinarof cream, 1% for the topical treatment of

FDA Accepts Supplemental New Drug Application for Tapinarof Cream, 1%, in Atopic Dermatitis

The acceptance is based on positive data from the phase 3 ADORING 1 and ADORING 2 pivotal trials, as well as interim results from the phase 3 ADORING 3 open-label, long-term extension trial.

Dermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

LONG BEACH, Calif. & BASEL, Switzerland (BUSINESS WIRE) Apr 29, 2024